March 1, 1998American Journal of HypertensionOpen Access

Antihypertensive Drug Treatment and Fibrinolytic Function

View Full Paper

Ask AI

Bookmark

Why the study?

Does antihypertensive drug treatment alter fibrinolytic function and protect against thromboembolic events in patients with arterial hypertension?

Population

Patients with arterial hypertension

Design

Review

Authors

KLK LottermoserMax Delbrück Center

Discussion

Member takes

Implication

Clinical data on fibrinolytic effects remain inconclusive; leaves open differential thromboembolic protection by antihypertensive class in hypertension.

Structured PICO

Does antihypertensive drug treatment alter fibrinolytic function and protect against thromboembolic events in patients with arterial hypertension?

Population

Patients with arterial hypertension

Intervention

Antihypertensive drug treatment (including diuretics, beta-blockers, calcium antagonists, ACE inhibitors, and angiotensin II receptor antagonists)

Outcome

Fibrinolytic function (balance between tissue-type plasminogen activator [t-PA] and plasminogen activator inhibitor 1 [PAI-1]) and thromboembolic events

Antihypertensive drugs may influence the fibrinolytic system, potentially explaining differences in protection against coronary versus cerebrovascular thromboembolic events, though clinical data remain inconclusive.

Cite This Study

K Lottermoser (1998) studied this question.

synapsesocial.com/papers/6a76a2c8a0847c3df1ec2022 https://doi.org/10.1016/s0895-7061(97)00496-2

Topics

Cardiovascular prevention

View Full Paper

Ask AI

Bookmark

Implication

Clinical data on fibrinolytic effects remain inconclusive; leaves open differential thromboembolic protection by antihypertensive class in hypertension.